



relieve™

Avisae OptimALL Nutrition relieve™

Optimal Inflammatory Response and Joint Relief Formula

Keep inflammation at bay with OptimALL Nutrition relieve! This unique product contains a proprietary formulation of ingredients provided by nature and supported by science that focuses on promoting a proper inflammatory response in the body. Included is OptimALL Nutrition Jointrestor™ a blend of powerful ingredients to help increase joint health, flexibility and mobility. OptimALL Nutrition Acticity™ has also been added to promote an optimal inflammatory response in your body. Its “best of science” ingredients make OptimALL Nutrition Relieve the perfect solution for your joint health and inflammation needs.*

Key Benefits

OptimALL Nutrition Jointrestor™

- Promotes joint comfort, mobility and flexibility*
- Provides nutrients to support healthy joints and cartilage*
- Supports a healthy and active lifestyle*
- Supports healthy vitamin D and calcium absorption*

OptimALL Nutrition Acticity™

- Encourages an optimal inflammatory response in the body*
- Delivers ingredients for fast action relief*

Product Features

- Features clinically proven, standardized ingredients
- Uses therapeutic doses supported by science
- Contains OptimALL Nutrition’s Bio-accelerate™ for improved nutrient absorption
- Made in the U.S.A. according to rigorous FDA GMP standards
- Free from preservatives, toxins, pesticides and heavy metals

*Contains: Shellfish (shrimp, crab, lobster, crayfish) ingredients.

*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure or prevent any disease.

Ingredient Information

Avisae OptimALL Nutrition Jointrestor™

Glucosamine sulfate

Glucosamine is a compound naturally produced in the body. It is a principal substance used in the production of certain macromolecules found in articular cartilage. Several randomized controlled clinical trials support the use of glucosamine sulfate in improving joint function and mobility, especially in the knees. These studies suggest glucosamine sulfate found in synovial fluid (joint lubricant) strengthens cartilage and aids the production of glycosaminoglycan. Glycosaminoglycans assist in the maintenance of joint tissue. Glycosaminoglycans also repair normal damage associated with everyday living and aging. Glucosamine may also have a mild effect on balancing inflammatory mediators. Since the vast majority of clinical studies used glucosamine sulfate, it is probable that other forms of glucosamine are ineffective.*

Calcium fructoborate (FruiteX-B®)

FruiteX-B is a fruit mineral complex found naturally in fruits, nuts, legumes and vegetables. The complex is chemically known as calcium fructoborate. FruiteX-B® is a significant breakthrough for those concerned with bone and joint health and healthy aging. In a pilot study, 79% of participants reported significant increases in joint comfort and flexibility after 8 weeks of supplementation. Participants in yet another study reported a 66% increase in knee comfort after taking FruiteX-B® in combination with vitamin C and vitamin D.*

FruiteX-B works by helping the body to maintain healthy levels of vitamin D. Better vitamin D metabolism can help the body absorb more calcium. Proper calcium levels play a major role in maintaining bone health. Extensive clinical research has also linked inadequate concentrations of vitamin D to the occurrence of nonspecific joint discomfort. *In vivo* studies have confirmed that FruiteX-B® can enter the bloodstream intact.*

Avisae OptimALL Nutrition Actisity™

White Willow (Salix alba) Bark Extract

Bark of the willow used as a natural remedy dates back to Hippocrates (400 BC). It has been used for hundreds of years in China and Europe as a relieving remedy. Today people use it to provide joint and back relief and to improve mobility and flexibility. White willow bark contains salicin, which is similar to the chemical found in aspirin. White willow was listed in the 1st through 10th editions of the United States Pharmacopoeia (USP) until it was replaced by aspirin.

This herb works by promoting a healthy balance of inflammatory mediators. White willow has been the subject of several randomized clinical trials, which have shown benefit to both the back and knees by improving joint comfort and mobility. Avisae OptimALL Nutrition Actisity™ includes a premium-quality willow bark extract standardized to 15% salicin to ensure consistent results.*

Bromelain

Bromelain is a proteolytic enzyme extracted from pineapple. It assists with the digestion of proteins and it helps promote a proper balance of inflammatory mediators such as thromboxane, kininogen and bradykinin. Introduced in 1957, Bromelain is regarded as safe and has been used in many clinical trials.*

*These statements have not been evaluated by the Food and Drug Administration.

This product is not intended to diagnose, treat, cure or prevent any disease.

Quercetin

Quercetin, an antioxidant flavonoid, occurs naturally in foods such as red wine, onions, green tea, apples, berries, broccoli, cauliflower, and cabbage. It has been used traditionally to support the cardiovascular system. Preclinical research suggests it helps by inhibiting the oxidation of LDL cholesterol. Randomized clinical trials have shown quercetin helps maintain normal blood pressure and promotes a healthy immune system after exercise.*

Resveratrol

Resveratrol, a powerful antioxidant and anti-aging nutrient, is a natural compound found in over 70 species of plants. It is a component of grapes, nuts, pine, and red wine. According to animal and preliminary research, Resveratrol may have various anti-aging benefits as well as have the ability to increase life span. Resveratrol is believed to be primary contributing factor of the “French paradox.” The French have significantly healthier cardiovascular systems when compared to other industrialized countries with similar risk profiles. Their healthy hearts are believed to be due in part to their consumption of red wine, which is rich in resveratrol.*

Myrrh, Yucca, and Saffron

Recorded in New Testament history, myrrh was given as a priceless gift to the newborn baby Jesus. Its use as a medicinal has been identified to go as far back as 5,000 years. Myrrh is a resin derived from the bark of Commiphora trees found primarily in Eastern Africa and Arabia. It is commonly used as an aromatic and incense. Traditionally, myrrh has been used for a variety of ailments including occasional indigestion, immune health, and joint mobility.*

Yucca, used for medicinal purposes, is derived from the root of the tree. Traditionally it is used for joint health, mild stomach discomfort and cardiovascular health. Some components of yucca have antioxidant properties. Based on preliminary research, resveratrol and yuccaols found in yucca may have the ability to promote a healthy inflammatory response in the body and help relieve stiffness.*

Saffron has a long historical use as a spice, medicine and coloring agent. One pound of saffron requires 75,000 blossoms, which are literally hand-picked. As a result of its limited ability to be harvested, saffron is one of the world’s most expensive spices. The price of one ounce of saffron can cost between \$50 and \$300. Its use was recorded by the Greek and Roman civilizations. Preclinical research evaluating the plant’s mechanisms of action demonstrate it has antioxidant properties, promotes a healthy inflammatory response, supports normal cell proliferation, and may support the cardiovascular system.*

References

1. Reginster, J. Y., Deroisy, R., Rovati, L. C., Lee, R. L., Lejeune, E., Bruyere, O., Giacovelli, G., Henrotin, Y., Dacre, J. E., and Gossett, C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. *Lancet* 1-27-2001;357(9252):251-256.
2. Pavelka, K., Gatterova, J., Olejarova, M., Machacek, S., Giacovelli, G., and Rovati, L. C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. *Arch.Intern.Med.* 10-14-2002;162(18):2113-2123.
3. Reichelt, A., Forster, K. K., Fischer, M., Rovati, L. C., and Setnikar, I. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double-blind study. *Arzneimittelforschung.* 1994;44(1):75-80.
4. D'Ambrosio, E., Casa, B., Bompani, R., Scali, G., and Scali, M. Glucosamine sulphate: a controlled clinical investigation in arthrosis. *Pharmatherapeutica* 1981;2(8):504-508.
5. Russell, A. I. and McCarty, M. F. Glucosamine in osteoarthritis. *Lancet* 11-6-1999;354(9190):1641-1642.
6. Drovanti, A., Bignamini, A. A., and Rovati, A. L. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo-controlled double-blind investigation. *Clin.Ther.* 1980;3(4):260-272.
7. Muller-Fassbender, H., Bach, G. L., Haase, W., Rovati, L. C., and Setnikar, I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. *Osteoarthritis Cartilage* 1994;2(1):61-69.
8. Noack W, Fischer M, Förster KK, and et al. Glucosamine sulfate in osteoarthritis of the knee. *Osteoarthritis Cartilage* 1994;2(1):51-59.
9. Pujalte, J. M., Llavore, E. P., and Ylescupidéz, F. R. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthritis. *Curr.Med Res.Opin.* 1980;7(2):110-114.
10. Rovati LC, Giacovelli G, Anfeld M, and et al. A large, randomised, placebo controlled, double-blind study of glucosamine sulfate vs. piroxicam and vs. their association, on the kinetics of the symptomatic effect in knee osteoarthritis [abstract]. *Osteoarthritis Cartilage* 1994;2(Suppl 1):56.
11. Lopes, Vaz A. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthritis of the knee in out-patients. *Curr.Med Res.Opin.* 1982;8(3):145-149.
12. Qiu, G. X., Gao, S. N., Giacovelli, G., Rovati, L., and Setnikar, I. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. *Arzneimittelforschung.* 1998;48(5):469-474.
13. Rindone, J. P., Hiller, D., Collacott, E., Nordhaugen, N., and Arriola, G. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. *West J Med* 2000;172(2):91-94.
14. Reginster JY, Deroisy R, Paul I, and et al. Glucosamine sulfate significantly reduces progression of the knee osteoarthritis over 3 years: a large randomised, placebo-controlled, double-blind, prospective trial. *Arthritis Rheum* 1999;42(9):S400.
15. Pavelka K, Gatterova J, Olejarova M, and et al. Glucosamine sulfate decreases progression of knee osteoarthritis in a long-term randomized placebo-controlled, independent, confirmatory trial. *Arthritis Rheum* 2000;43(9 (suppl)):S384.
16. Cibere, J., Kopec, J. A., Thorne, A., Singer, J., Canvin, J., Robinson, D. B., Pope, J., Hong, P., Grant, E., and Esdaile, J. M. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. *Arthritis Rheum* 10-15-2004;51(5):738-745.
17. Hughes, R. and Carr, A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. *Rheumatology.(Oxford)* 2002;41(3):279-284.
18. Thie, N. M., Prasad, N. G., and Major, P. W. Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial. *J Rheumatol.* 2001;28(6):1347-1355.
19. Tapadinhas, M. J., Rivera, I. C., and Bignamini, A. A. Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal. *Pharmatherapeutica* 1982;3(3):157-168.

*These statements have not been evaluated by the Food and Drug Administration.

This product is not intended to diagnose, treat, cure or prevent any disease.

20. Chrubasik, S., Eisenberg, E., Balan, E., Weinberger, T., Luzzati, R., and Conradt, C. Treatment of low back pain exacerbations with willow bark extract: a randomized double-blind study. *Am J Med* 2000;109(1):9-14.
21. Chrubasik, S., Kunzel, O., Model, A., Conradt, C., and Black, A. Treatment of low back pain with a herbal or synthetic anti-rheumatic: a randomized controlled study. Willow bark extract for low back pain. *Rheumatology (Oxford)* 2001;40(12):1388-1393.
22. Black A, Kunzel O, Chrubasik S, and et al. Economics of using willow bark extract in outpatient treatment of low back pain [abstract]. 8th Annual Symposium on Complementary Health Care, 6th-8th December 2001 2001.
23. Biegert, C., Wagner, I., Ludtke, R., Kotter, I., Lohmuller, C., Gunaydin, I., Taxis, K., and Heide, L. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials. *J.Rheumatol.* 2004;31(11):2121-2130.
24. Mills, S. Y., Jacoby, R. K., Chacksfield, M., and Willoughby, M. Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: a double-blind study. *Br.J Rheumatol.* 1996;35(9):874-878.
25. Schmid, B., Ludtke, R., Selbmann, H. K., Kotter, I., Tschirdewahn, B., Schaffner, W., and Heide, L. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: randomized placebo-controlled, double blind clinical trial. *Phytother Res* 2001;15(4):344-350.
26. Hotz, G., Frank, T., Zoller, J., and Wiebelt, H. [Antiphlogistic effect of bromelaine following third molar removal]. *Dtsch Zahnarztl.Z.* 1989;44(11):830-832.
27. Howat, R. C. and Lewis, G. D. The effect of bromelain therapy on episiotomy wounds--a double blind controlled clinical trial. *J Obstet.Gynaecol.Br.Commonw.* 1972;79(10):951-953.
28. Mader, H. [Comparative studies on the effect of bromelin and oxyphenbutazone in episiotomy pains]. *Schweiz Rundsch.Med Prax.* 8-28-1973;62(35):1064-1068.
29. Korlof, B., Ponten, B., and Ugland, O. Bromelain--a proteolytic enzyme. *Scand.J.Plast.Reconstr.Surg.* 1969;3(1):27-29.
30. Morrison AW and Morrison MC. Bromelain - a clinical assessment in the post-operative treatment of arthrotomies of the knee and facial injuries. *Brit J Clin Pract* 1965;19(4):207-210.
31. Tassman GC, Zafran JN, and Zayon GM. A double-blind crossover study of a plant proteolytic enzyme in oral surgery. *J Dent Med* 1965;20(2):51-54.
32. Cowie, D. H., Fairweather, D. V., and Newell, D. J. A double-blind trial of bromelains as an adjunct to vaginal plastic repair operations. *J Obstet Gynaecol Br Commonw.* 1970;77(4):365-368.
33. Seligman, B. Oral bromelains as adjuncts in the treatment of acute thrombophlebitis. *Angiology* 1969;20(1):22-26.
34. Seltzer, A. P. Minimizing post-operative edema and ecchymoses by the use of an oral enzyme preparation (bromelain). A controlled study of 53 rhinoplasty cases. *Eye Ear Nose Throat Mon.* 1962;41:813-817.
35. Edwards, R. L., Lyon, T., Litwin, S. E., Rabovsky, A., Symons, J. D., and Jalili, T. Quercetin reduces blood pressure in hypertensive subjects. *J Nutr* 2007;137(11):2405-2411.
36. Conquer, J. A., Maiani, G., Azzini, E., Raguzzini, A., and Holub, B. J. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. *J.Nutr.* 1998;128(3):593-597.
37. Nieman, D. C., Henson, D. A., Davis, J. M., Angela, Murphy E., Jenkins, D. P., Gross, S. J., Carmichael, M. D., Quindry, J. C., Dumke, C. L., Utter, A. C., McAnulty, S. R., McAnulty, L. S., Triplett, N. T., and Mayer, E. P. Quercetin's influence on exercise-induced changes in plasma cytokines and muscle and leukocyte cytokine mRNA. *J Appl Physiol* 2007;103(5):1728-1735.
38. Nieman, D. C., Henson, D. A., Gross, S. J., Jenkins, D. P., Davis, J. M., Murphy, E. A., Carmichael, M. D., Dumke, C. L., Utter, A. C., McAnulty, S. R., McAnulty, L. S., and Mayer, E. P. Quercetin reduces illness but not immune perturbations after intensive exercise. *Med Sci Sports Exerc.* 2007;39(9):1561-1569.
39. Nieman, D. C. Immunonutrition support for athletes. *Nutr Rev.* 2008;66(6):310-320.

*These statements have not been evaluated by the Food and Drug Administration.

This product is not intended to diagnose, treat, cure or prevent any disease.

40. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L. L., Scherer, B., and Sinclair, D. A. Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature* 9-11-2003;425(6954):191-196.
41. Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., and Sinclair, D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. *Nature* 8-5-2004;430(7000):686-689.
42. Baur, J. A. and Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. *Nat Rev Drug Discov.* 2006;5(6):493-506.
43. Gruber, J., Tang, S. Y., and Halliwell, B. Evidence for a trade-off between survival and fitness caused by resveratrol treatment of *Caenorhabditis elegans*. *Ann N Y Acad Sci* 2007;1100:530-542.
44. Bass, T. M., Weinkove, D., Houthoofd, K., Gems, D., and Partridge, L. Effects of resveratrol on lifespan in *Drosophila melanogaster* and *Caenorhabditis elegans*. *Mech.Ageing Dev* 2007;128(10):546-552.
45. Valenzano, D. R., Terzibasi, E., Genade, T., Cattaneo, A., Domenici, L., and Cellerino, A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. *Curr Biol* 2-7-2006;16(3):296-300.
46. Pearson, K. J., Baur, J. A., Lewis, K. N., et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. *Cell Metab* 2008;8(2):157-168.
47. Rimando, A. M. and Suh, N. Biological/chemopreventive activity of stilbenes and their effect on colon cancer. *Planta Med* 2008;74(13):1635-1643.
48. Orallo, F. Trans-resveratrol: a magical elixir of eternal youth? *Curr.Med Chem.* 2008;15(19):1887-1898.
49. Pirola, L. and Frojdo, S. Resveratrol: one molecule, many targets. *IUBMB.Life* 2008;60(5):323-332.
50. Singh, R. B., Niaz, M. A., and Ghosh, S. Hypolipidemic and antioxidant effects of *Commiphora mukul* as an adjunct to dietary therapy in patients with hypercholesterolemia. *Cardiovasc.Drugs Ther* 1994;8(4):659-664.
51. Dolara, P., Luceri, C., Ghelardini, C., Monserrat, C., Aiolfi, S., Luceri, F., Lodovici, M., Menichetti, S., and Romanelli, M. N. Analgesic effects of myrrh. *Nature* 1-4-1996;379(6560):29.
52. Al Awadi, F. M. and Gumaa, K. A. Studies on the activity of individual plants of an antidiabetic plant mixture. *Acta Diabetol.Lat.* 1987;24(1):37-41.
53. Andersson, M., Bergendorff, O., Shan, R., Zygmunt, P., and Sterner, O. Minor components with smooth muscle relaxing properties from scented myrrh (*Commiphora guidotti*). *Planta Med* 1997;63(3):250-254.
54. Dolara, P., Corte, B., Ghelardini, C., Pugliese, A. M., Cerbai, E., Menichetti, S., and Lo, Nostro A. Local anaesthetic, antibacterial and antifungal properties of sesquiterpenes from myrrh. *Planta Med* 2000;66(4):356-358.
55. Agarwal, R. C., Singh, S. P., Saran, R. K., Das, S. K., Sinha, N., Asthana, O. P., Gupta, P. P., Nityanand, S., Dhawan, B. N., and Agarwal, S. S. Clinical trial of guggulipid--a new hypolipidemic agent of plant origin in primary hyperlipidemia. *Indian J Med Res* 1986;84:626-634.
56. Malhotra, S. C., Ahuja, M. M., and Sundaram, K. R. Long term clinical studies on the hypolipidaemic effect of *Commiphora mukul* (Guggulu) and clofibrate. *Indian J Med Res* 1977;65(3):390-395.
57. Lata S and et al. Beneficial effects of *Allium sativum*, *Allium cepa* and *Commiphora mukul* on experimental hyperlipidemia and atherosclerosis - a comparative evaluation. *J Postgrad Med* 1991;37:132.
58. Kim, S. W., Park, S. K., Kang, S. I., Kang, H. C., Oh, H. J., Bae, C. Y., and Bae, D. H. Hypocholesterolemic property of *Yucca schidigera* and *Quillaja saponaria* extracts in human body. *Arch Pharm.Res* 2003;26(12):1042-1046.
59. Favel, A., Kemertelidze, E., Benidze, M., Fallague, K., and Regli, P. Antifungal activity of steroidal glycosides from *Yucca gloriosa* L. *Phytother.Res* 2005;19(2):158-161.
60. Balestrieri, C., Felice, F., Piacente, S., Pizza, C., Montoro, P., Oleszek, W., Visciano, V., and Balestrieri, M. L. Relative effects of phenolic constituents from *Yucca schidigera* Roezl. bark on Kaposi's sarcoma cell proliferation, migration, and PAF synthesis. *Biochem Pharmacol* 5-14-2006;71(10):1479-1487.
61. Nishino, H., Murakosh, M., li, T., Takemura, M., Kuchide, M., Kanazawa, M., Mou, X. Y., Wada, S., Masuda, M.,

*These statements have not been evaluated by the Food and Drug Administration.

This product is not intended to diagnose, treat, cure or prevent any disease.

- Ohsaka, Y., Yogosawa, S., Satomi, Y., and Jinno, K. Carotenoids in cancer chemoprevention. *Cancer Metastasis Rev.* 2002;21(3-4):257-264.
62. Nair, S. C., Pannikar, B., and Panikkar, K. R. Antitumour activity of saffron (*Crocus sativus*). *Cancer Lett.* 5-1-1991;57(2):109-114.
63. Assimopoulou, A. N., Sinakos, Z., and Papageorgiou, V. P. Radical scavenging activity of *Crocus sativus* L. extract and its bioactive constituents. *Phytother.Res* 2005;19(11):997-1000.
64. Nair, S. C., Kurumboor, S. K., and Hasegawa, J. H. Saffron chemoprevention in biology and medicine: a review. *Cancer Biother.* 1995;10(4):257-264.
65. Grisolia, S. Letter: Hypoxia, saffron, and cardiovascular disease. *Lancet* 7-6-1974;2(7871):41-42.
66. Shen, X. C. and Qian, Z. Y. Effect of crocetin on cardiac hypertrophy induced by overloading pressure in rats. *Yao Xue.Xue.Bao.* 2004;39(3):172-175.
67. Kazi, H. A. and Qian, Z. Crocetin reduces TNBS-induced experimental colitis in mice by downregulation of NFkB. *Saudi J Gastroenterol.* 2009;15(3):181-187.
68. Hosseinzadeh, H. and Younesi, H. M. Antinociceptive and anti-inflammatory effects of *Crocus sativus* L. stigma and petal extracts in mice. *BMC.Pharmacol* 3-15-2002;2:7.
69. Wang, C. J., Lee, M. J., Chang, M. C., and Lin, J. K. Inhibition of tumor promotion in benzo[a]pyrene-initiated CD-1 mouse skin by crocetin. *Carcinogenesis* 1995;16(2):187-191.
70. Yan, J., Qian, Z., Sheng, L., Zhao, B., Yang, L., Ji, H., Han, X., and Zhang, R. Effect of crocetin on blood pressure restoration and synthesis of inflammatory mediators in heart after hemorrhagic shock in anesthetized rats. *Shock* 2010;33(1):83-87.